EurekAlert! -
28 Apr 2014 06:00
(Elsevier Health Sciences) The adhesion molecule CD146 plays a vital role in inflammation and offers a promising therapeutic target for treating inflammatory bowel disease as well as preventing colitis-associated colorectal cancer, say scientists. Targeting CD146 with anti-CD146 antibody AA98, especially in combination with an anti-TNF-alpha antibody, showed promising results in mice. Their report is published in The American Journal of Pathology.
Share this Article